氯沙坦钾对慢性心力衰竭患者尿液水通道蛋白2的影响.pdfVIP

484 Journal of Medical Science in Central South China,Sep2012,Vol.40,No.5 文章编号:2095-1116(2012)05-0484-03 ·临床医学· 氯沙坦钾对慢性心力衰竭患者尿液水通道蛋白2 的影响 欧阳劭,陈摇 伟 (南华大学附属第二医院心血管内科,湖南衡阳421001) 摘摇 要:摇 目的摇 探讨氯沙坦钾对慢性心力衰竭患者尿液水通道蛋白2(AQP2)浓度的影响。 摇 方法摇 慢性心 力衰竭(CHF)患者203例,分为常规治疗组(100例)和氯沙坦钾组(103例),另设正常对照组(50例),用放射免疫 法检测血浆血管加压素(AVP)浓度、间接ELISA 法检测尿液AQP2 浓度,用药12周,治疗前后各1天采血检测血浆 AVP 浓度、留尿检测尿液AQP2 浓度,比较其变化。 摇 结果摇 与正常对照组比较,氯沙坦钾组治疗前后 AVP 和 AQP2 浓度均显著升高(P 均0.05),常规治疗组治疗前后AVP和AQP2 浓度均显著升高(P 均0.05)。 氯沙坦 钾组治疗后AVP和AQP2 浓度低于药物治疗前,也低于常规组治疗后(P 均0.05)。 摇 结论摇 CHF 患者尿液 AQP2排出增多,氯沙坦钾减少尿液AQP2排出,抑制集合管对水的重吸收,减轻水钠潴留,减轻心脏前负荷,延缓 心力衰竭发展。 关键词:摇 心力衰竭;摇 水通道蛋白2;摇 血管加压素;摇 氯沙坦钾 中图分类号:R541郾6摇 摇 摇 文献标识码:A Effects of Losartan Potassium on the Concentration of Urine Aquaporin鄄2 in Congestive Heart Failure Patient OUYANG Shao,CHEN Wei (Department of Cardiovascular,the SecondAffiliated Hospital,University of South China, Hengyang,Hunan421001,China) Abstract:摇 Objective摇 To investigate effects of losartan potassium on the concentration of urine aquaporin鄄2 (u鄄 AQP2) in congestive heart failure patients.摇 Methods摇 203 patients with CHF were randomly divided into two groups: losartan potassium group (103 cases) and general treatment group (100 cases).These patients were compared against 50 normal control subjects.In all subjects,the concentration of plasma arginine vasopressin (p鄄AVP) were detected by radio鄄 immunoassay (RIA),the concentration of u鄄AQP2 were detected by indirect enzyme linked immunosorbent assay (indirect ELISA),to analyse the relationship of u鄄AQP2 and p鄄AVP before and after 12 week treatment.摇 Res